Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...
The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...
Scientists have used AI to identify two novel subtypes of multiple sclerosis (MS), which could offer new, targeted treatments ...
England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...
HOUSTON and WALTHAM, Mass., April 17, 2025 /PRNewswire/ -- Biostate AI, a leading innovator in artificial intelligence for RNA sequencing, today announced a strategic partnership with the Accelerated ...
Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.
NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback